S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 98-99
10.1097/01.hs9.0000843680.94912.c5